![Henrik Elofsson](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Henrik Elofsson
Career history of Henrik Elofsson
Former positions of Henrik Elofsson
Companies | Position | Start | End |
---|---|---|---|
MENDUS AB | Chief Operating Officer | 30/06/2013 | - |
Arterion AB
![]() Arterion AB BiotechnologyHealth Technology Arterion AB is a holding company that manufactures biomaterials, including artificial blood vessels, consisting of microbial derived cellulose for revascularization of patients with cardiovascular diseases. It focuses on pure uncoated cellulose grafts as replacement of human vessels, primarily as bypass grafts. Its manufacturing method is based on a novel technology that controls the life conditions of the microbe Gluconacetobacter xylinus. Its use of microbial derived cellulose will allow clinicians to use artificial blood vessels as replacement for vessels with an internal diameter of less than five millimeters. The company was founded on January 4, 2007 and is headquartered in Gothenburg, Sweden. | Director/Board Member | 02/09/2010 | - |
Founder | 31/12/2006 | - | |
Corporate Officer/Principal | 02/09/2010 | 10/06/2013 |
Training of Henrik Elofsson
University of Linköping | Undergraduate Degree |
Chalmers School of Entrepreneurship | Graduate Degree |
Statistics
International
Sweden | 5 |
Operational
Director/Board Member | 1 |
Founder | 1 |
Corporate Officer/Principal | 1 |
Sectoral
Health Technology | 3 |
Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
MENDUS AB | Health Technology |
Private companies | 1 |
---|---|
Arterion AB
![]() Arterion AB BiotechnologyHealth Technology Arterion AB is a holding company that manufactures biomaterials, including artificial blood vessels, consisting of microbial derived cellulose for revascularization of patients with cardiovascular diseases. It focuses on pure uncoated cellulose grafts as replacement of human vessels, primarily as bypass grafts. Its manufacturing method is based on a novel technology that controls the life conditions of the microbe Gluconacetobacter xylinus. Its use of microbial derived cellulose will allow clinicians to use artificial blood vessels as replacement for vessels with an internal diameter of less than five millimeters. The company was founded on January 4, 2007 and is headquartered in Gothenburg, Sweden. | Health Technology |
- Stock Market
- Insiders
- Henrik Elofsson
- Experience